Methods are disclosed for dissecting a mucosa and a submucosa from a muscularis propria from a region of an esophagus of a subject. These methods include injecting submucosally into the esophagus of the subject a pharmaceutical composition comprising an extracellular matrix (ECM) hydrogel to form a cushion between the submucosa and the underlying muscularis propria at the region of the esophagus, wherein the ECM hydrogel has the following characteristics: a) a time to 50% gelation of less than 30 minutes at a temperature of about 37° C.; b) a flow viscosity suitable for infusion into the esophagus; and c) a stiffness of about 10 to about 400 Pascal (Pa). The ECM hydrogel is not a urinary bladder ECM hydrogel.

The purpose of the present invention is to provide (i) a method for maintaining or enhancing the activity of a cell mass separated from an epithelial tissue; (ii) a method for increasing the proliferation ability of cells in an epithelial tissue; (iii) a method for producing a cell mass employing these methods; (iv) a pharmaceutical composition containing the cell mass; and, (v) a method for treating a disease using the cell mass. The purpose is fulfilled by culturing a cell mass separated from an epithelial tissue or an epithelial tissue with a thermoreversible polymer.

The purpose of the present invention is to provide (i) a method for maintaining or enhancing the activity of a cell mass separated from an epithelial tissue; (ii) a method for increasing the proliferation ability of cells in an epithelial tissue; (iii) a method for producing a cell mass employing these methods; (iv) a pharmaceutical composition containing the cell mass; and, (v) a method for treating a disease using the cell mass. The purpose is fulfilled by culturing a cell mass separated from an epithelial tissue or an epithelial tissue with a thermoreversible polymer.

An object of the present invention is to provide a method of producing an intestinal epithelial cell, which has a large number of cells per area and a high accuracy of kinetic prediction for a CYP3A4 substrate drug such as midazolam, by inducing the differentiation of a pluripotent stem cell, as well as the intestinal epithelial cell, a cell sheet, an evaluation method for a test substance, a screening kit for a test substance, and a cell preparation. According to the present invention, there is provided a production method for an intestinal epithelial cell, including a first differentiation step of differentiating a pluripotent stem cell into an intestinal stem cell, a proliferation step of proliferating the intestinal stem cell obtained in the differentiation step, and a second differentiation step of differentiating the intestinal stem cell obtained in the proliferation step into an intestinal epithelial cell, in which the proliferation step is a step of bringing the intestinal stem cell into a specific state.

The kidney regeneration accelerator that contains a component obtained by decellularizing a mammalian organ. The production method for a kidney regeneration accelerator that involves decellularizing a mammalian organ to obtain a component that includes an extracellular matrix, freeze drying and then pulverizing the component to obtain a powder, and performing a sterilization treatment on the powder. A pharmaceutical composition for use in treating kidney disease that contains a component obtained by decellularizing a mammalian organ. A treatment method for kidney disease that involves applying a pharmaceutical composition that contains a component obtained by decellularizing a mammalian organ to a site to be treated of the kidney of a human or animal kidney disease patient.

The subject matter disclosed herein is generally directed to modulation of genes and pathways that drive differentiation of LGR5+ stem cells. The methods and compositions can be used to treat diseases associated with aberrant epithelial barrier function.

The subject matter disclosed herein is generally directed to modulation of genes and pathways that drive differentiation of LGR5+ stem cells. The methods and compositions can be used to treat diseases associated with aberrant epithelial barrier function.

Methods for using cyclin-dependent kinase (CDK) inhibitors to enhance growth and self-renewal of progenitor cells, in vitro and in vivo.

Production of “regenerative medicine products” is facilitated using a quality by design (QbD) approach. A production device produces a medical product and analyzes a starting material and a central management device determines processing conditions in the production device. By transmitting and receiving data pertaining to the starting material between the production device and central management device data, the medical product is produced while production conditions therefor are continuously optimized. Thus, it is easy to produce a medical product while reducing or eliminating effects from changes in cells and tissues over time, from oscillation during transport, and from changes in surrounding environment such as changes in temperature, and to produce the desired medical product even when there are individual differences in the starting material.

Production of “regenerative medicine products” is facilitated using a quality by design (QbD) approach. A production device produces a medical product and analyzes a starting material and a central management device determines processing conditions in the production device. By transmitting and receiving data pertaining to the starting material between the production device and central management device data, the medical product is produced while production conditions therefor are continuously optimized. Thus, it is easy to produce a medical product while reducing or eliminating effects from changes in cells and tissues over time, from oscillation during transport, and from changes in surrounding environment such as changes in temperature, and to produce the desired medical product even when there are individual differences in the starting material.